1.. INTRODUCTION
================

Although all nucleated cells contain the same genetic information, multicellular organisms have evolved elaborate mechanisms that enable differential and cell-type specific gene expression. Epigenetics refers to the heritable changes that control how the genome is accessed in different cell types during embryonic development and cellular differentiation \[[@R1]\]. This capability permits specialization of function between cells without altering the DNA sequence. The cellular machinery that creates these heritable changes has been the subject of intense scientific investigation over the last decade \[[@R2]\].

The epigenome is a group of proteins that regulate gene expression and is responsible for cell differentiation \[[@R2]\]. The template upon which the epigenome is written is chromatin -- the complex of DNA, histones and other structural proteins that efficiently package the genome in an appropriately accessible state within each cell \[[@R3], [@R4]\]. Regulation of chromatin state plays an important role in the fields of epigenetics, oncology, developmental biology, stem cell fate and regenerative medicine. The state of chromatin, and thus access to the genetic code, is mainly regulated by reversible post-translational modifications (PTMs) to DNA or histone proteins and the recognition of these marks by other proteins and protein complexes. Histones are subject to various kinds of PTMs, including methylation, acetylation, phosphorylation, sumoylation, ubiquitination, and glycosylation \[[@R5], [@R6]\]. The addition, interpretation and removal of these PTM marks are crucial to gene transcription. Proteins that are directly involved in PTMs are often classified into three functional families: the enzymes that produce these modifications (the 'writers'), the proteins that recognize them (the 'readers'), and the enzymes that remove them (the 'erasers'). Given the wide-spread importance of chromatin regulation in cell biology, the 'writers', 'readers', and 'erasers' are critical targets for manipulation to further understand the histone code \[[@R7], [@R8]\] and the role it plays in the progression of human disease.

Histone methylation, which mainly occurs at lysine and arginine residues located on the *N*-terminal tails of the core histones, is one of the most studied PTM marks \[[@R9]\]. Protein lysine methyltransferases (PKMTs) and protein arginine methyltransferases (PRMTs) are two of the writers responsible for adding the methyl marks to histones \[[@R10]\]. Recently, it has also been shown that these writers are capable of methylating other functionally important proteins, including p53, ERα, pRb, TAF10, and HIV tat \[[@R11]-[@R14]\]. Both *in vitro* and cell-based studies have suggested that methyltransferases are responsible for methylating only specific residues, which is referred to as substrate selectivity. Moreover, these writers only methylate the residue to a specific methylation level, which is known as product specificity. For example, lysine residues can be mono-, di- or trimethylated (Scheme **[1A](#S1){ref-type="scheme"}**), while arginines can be mono- or dimethylated in either a symmetric (sDMA) or asymmetric (aDMA) manner (Scheme **[1B](#S1){ref-type="scheme"}**). Table **[1](#T1){ref-type="table"}** lists known histone methyl marks, their corresponding methyltransferases, and potential function and links to disease. Several experimental and theoretical groups have recently investigated the detailed catalytic mechanism, especially in regard to how writers achieve their substrate selectivity and product specificity \[[@R15]-[@R19]\]. These studies are not the subject of this review.

PKMTs and PRMTs have two binding pockets: the substrate binding pocket and a cofactor binding site \[[@R68]\]. Upon activation, the writer recruits the lysine or arginine residue of the histone tail to the substrate binding pocket and a universal methyl donor, *S*-5'-adenosyl-L-methionine (SAM), to the cofactor binding site \[[@R5]\]. As shown in Fig. (**[1](#F1){ref-type="fig"}**), the substrate binding pocket and the cofactor binding site are joined by a narrow hydrophobic channel, just large enough to allow the terminal amine of the substrate to come within bonding distance of the cofactor. The terminal amine undergoes nucleophilic substitution with SAM, transferring the methyl group to the target residue, converting SAM to *S*-adenosyl-L-homocysteine (SAH) which is then released by the enzyme. In some cases, depending on the enzyme, this process can be repeated to add subsequent methyl groups to the lysine or arginine residue.

Growing evidence suggests that PKMTs and PRMTs are associated with the development of various human diseases, including cancer, inflammation, and psychiatric disorders \[[@R69]-[@R71]\]. For example, H3K9 methyltransferase G9a is overexpressed in various human cancers \[[@R26]-[@R29]\] including leukemia, prostate carcinoma, hepatocellular carcinoma, and lung cancer and has been shown to play a role in mental retardation \[[@R72]\], inflammation \[[@R33]\], drug addiction \[[@R73]\] and HIV-1 latency maintenance \[[@R74]\]. Another PKMT, DOT1L, can be recruited by AF10, an MLL (mixed lineage leukemia) or CALM (clathrin-assembly protein-like lymphoid--myeloid) fusion partner involved in acute myeloid leukemia \[[@R51], [@R52]\]. Direct fusion of DOT1L to MLL results in leukemic transformation in a DOT1L methyltransferase activity-dependent manner \[[@R52]\]. In addition, DOT1L contributes to CALM--AF10-mediated leukaemogenesis by methylation of H3K79 at the Hoxa5 gene \[[@R51]\]. PRMT4 \[better known as coactivator-associated arginine methyltransferase 1 (CARM1)\] enhances transcriptional activation of nuclear receptors and aberrant expression of this methyltransferase has been linked to human breast and castration-resistant prostate cancers \[[@R60], [@R61]\]. Given the significant role of these proteins in human disease, the discovery of potent, selective, and cell penetrant chemical probes of PKMTs and PRMTs is gaining momentum. In addition to providing the scientific community excellent tools for further studying chromatin remodeling and other PTMs, high quality well characterized chemical probes \[[@R75]\] can facilitate a smooth transition from target validation to a drug development effort. In this review, we will focus on the recent progress in the discovery of selective PKMT and PRMT inhibitors. A future perspective on developing methyltransferase inhibitors will also be discussed. Nucleoside-based inhibitors (analogs of cofactor SAM) such as sinefungin and methylthioadenosine and bisubstrate analogs containing structural components of both SAM and the substrate peptide will not be discussed in this review as these cofactor analogs are not selective in general \[[@R76]-[@R79]\].

2.. PROTEIN LYSINE METHYLTRANSFERASES (PKMTs)
=============================================

PKMTs can mono-, di-, and/or trimethylate lysine residues of various proteins including histones. Protein lysine methylation is involved in many biological processes, such as heterochromatin formation, gene expression, transcriptional regulation and X-chromosome inactivation \[[@R9]\]. Since the first PKMT was characterized in 2000 \[[@R80]\], more than 50 human PKMTs have been identified and over 10 high-resolution 3-dimensional (3-D) structures have been reported \[[@R5], [@R9], [@R69], [@R81]-[@R85]\]. PKMTs are classified based on the presence or absence of the evolutionarily conserved SET domain, named after *Drosophila*[S]{.ul}u(var)3-9 (suppressor of variegation 3-9), [E]{.ul}(z) (enhancer of zeste), and [t]{.ul}rithorax \[[@R86]\]. The SET domain containing PKMTs are further categorized into five subfamilies named after their founding members: RIZ, SET1, SET2, SMYD3 and SUV39 \[[@R82]\].

A number of lysine methylation sites of H3 and H4 have been well characterized \[[@R87]\]. Unlike acetylation which generally correlates with transcriptional activation \[[@R3]\], histone lysine methylation can either activate or repress transcription depending on the site of methylation. For example, methylation at H3K4, H3K36 and H3K79 has been linked to actively transcribed genes, whereas methylated H3K9, H3K27 and H4K20 are considered repressive marks \[[@R88]\]. In addition to histones, other proteins have been identified as PKMT substrates \[[@R12], [@R13], [@R89]-[@R91]\]. One such example, the tumor suppressor protein p53, implicated in over 50% of cancers \[[@R92]\], can be methylated by various PKMTs with contrasting effects depending on the site of lysine methylation. For instance, methylation of p53 on K370 by SMYD2 \[[@R51]\] or on K382 by SETD8 \[[@R13]\] results in transcriptional repression, whereas methylation at K372 by SET7/9 leads to activation of transcription \[[@R12]\]. In addition, G9a (also known as EHMT2) and GLP (also known as EHMT1), which share 80% sequence homology in their respective SET domains \[[@R84], [@R93]\], have been found to methylate p53 at K373, correlating with inactivation of p53 \[[@R92]\].

2.1.. PKMT Inhibitors
---------------------

In 2005, Greiner and co-workers screened a library of ca. 3,000 compounds using a standard radioactive filter-binding assay \[[@R94]\] and identified chaetocin (Fig. **[2](#F2){ref-type="fig"}**), a fungal mycotoxin, as the first small-molecule inhibitor of recombinant *Drosophila* Su(var)3-9 (IC~50~ = 0.6 µM). Chaetocin was also found to inhibit H3K9 PKMT SUV39H1 (IC~50~ = 0.8 µM), the human orthologue of dSu(var)3-9. While chaetocin inhibited other H3K9 PKMTs, including *Neurospora* DIM5 (IC~50~ = 3.0 µM) and mouse G9a (IC~50~ = 2.5 µM), it was selective over non-H3K9 PKMTs, such as H3K27 PKMT dE(z) complex, H3K4 PKMT SET7/9, and H4K20 PKMT SETD8 \[[@R94]\] (IC~50~ dE(z) complex \> 90 µM; SET7/9 and SETD8 \>180 µM). Furthermore, mechanistic studies characterized chaetocin as a SAM-competitive inhibitor, which remained active even after the disulfide bonds of chaetocin were reduced in the presence of increasing amounts of dithiothreitol (DTT) \[[@R94]\]. Interestingly, a total synthesis report found both natural (+)- and synthetic (--)-chaetocin to be equipotent against G9a (IC~50~ = 2.4 and 1.7 µM, respectively) while the sulfur-deficient analogs were inactive (IC~50~ \> 50 µM, Fig. **[2](#F2){ref-type="fig"}**) \[[@R95]\]. Like other members of the epidithiodiketopiperazine (ETP) class \[[@R96]\], chaetocin is cytotoxic, although dependent on initial cell density. Chaetocin-treated *Drosophila* SL-2 cells at an inhibitor concentration of 0.5 µM showed marked cellular reduction of di- and trimethylation levels of H3K9 with no apparent changes in the degree of methylation of other lysines (H3K27, H3K36, H3K79, and H3K4) \[[@R94]\].

A high throughput screen of ca. 125,000 compounds, preselected from the Boehringer Ingelheim (BI) compound collection, revealed BIX01294 (Fig. **[2](#F2){ref-type="fig"}**) as the first selective small-molecule inhibitor of G9a and GLP with low micromolar potency *in vitro* over other H3K9 PKMTs (SUV39H1 and SETDB1), H3K4 PKMT SET7/9, and arginine methyltransferase PRMT1, which all showed no inhibition at concentrations of 45 µ M \[[@R93]\]. Under linear assay conditions, BIX01294 inhibited G9a and GLP with IC~50~ values of 1.9 µ M and 0.7 µ M, respectively \[[@R84]\]. In cellular assays, BIX01294 was toxic at high concentrations (\> 4.1 µ M). However, when cells were treated at an inhibitor concentration of 4.1 µ M, BIX01294 reduced H3K9me2 levels of bulk histones, while methylation levels of other known sites, including H3K27, H3K36, and H4K20, remained largely unchanged. Mechanistically, unlike chaetocin, BIX01294 did not inhibit G9a in a SAM-competitive manner but rather occupied the histone peptide binding pocket, as confirmed by the X-ray crystal structure of BIX01294 and GLP in the presence of SAH (Fig. **[3A](#F3){ref-type="fig"}**, PDB: 3FPD) \[[@R84],[@R93]\]. Interestingly, the X-ray structure revealed that while BIX01294 did not bind in the SAM-binding site, it also did not interact with the lysine binding channel \[[@R84]\]. Through the same high-throughput screen as mentioned above, non-selective lysine and arginine methyltransferase inhibitors, such as BIX01338, were also discovered (Fig. **[2](#F2){ref-type="fig"}**) \[[@R93]\].

Structure-activity relationships (SAR) of the quinazoline scaffold exemplified by BIX01294 were investigated based on the reported X-ray structure of the GLP-BIX01294 complex (Fig. **[3A](#F3){ref-type="fig"}**). Tractable SAR were demonstrated for the 2- and 4-amino moieties \[[@R85], [@R97]\]. To improve potency, the 7-methoxy moiety of the quinazoline template was explored in an attempt to design analogs that would interact with the lysine binding channel. These efforts resulted in the discovery of UNC0224 (Fig. **[4](#F4){ref-type="fig"}**) as a seven times more potent G9a inhibitor (IC~50~ = 15 nM) when compared to BIX01294 (IC~50~ = 106 nM) in the G9a ThioGlo assay \[[@R85], [@R98]\]. The higher potency of UNC0224 was confirmed by isothermal titration calorimetry (ITC) (*K*~d~ = 23 nM; BIX01294 *K*~d~= 130 nM) \[[@R85]\]. Although UNC0224 was equipotent against GLP with an IC~50~ of 20 nM, it was more than 1,000-fold selective for G9a over other PKMTs, including SET7/9 and SETD8. In addition, UNC0224 was clean against a broad panel of G-protein coupled receptors, ion channels, and transporters \[[@R85]\]. A high resolution (1.7 Å) X-ray co-crystal structure of G9a and UNC0224 (PDB: 3K5K) was obtained, providing the first crystal structure of G9a in complex with a small molecule inhibitor (Fig. **[3B](#F3){ref-type="fig"}**). Indeed, the structure showed the 7-dimethylamino propoxy side chain of UNC0224 occupying the lysine binding channel of G9a, validating the design rationale for UNC0224 and providing an explanation for its higher potency \[[@R84], [@R85]\]. However, the 7-alkoxy side chain did not completely occupy the lysine binding channel, and space remained for the channel to accommodate a longer side chain or larger amino-capping group. Therefore, additional SAR of the 7-alkoxy side chain of UNC0224 was investigated. These side chain optimization efforts led to the discovery of UNC0321 (Fig. **[4](#F4){ref-type="fig"}**), the most potent G9a inhibitor to date (IC~50~ = 6 nM, AlphaScreen; 9 nM, ThioGlo) \[[@R97]\]. Because UNC0321 likely reached the detection limits of the biochemical assays, Morrison *K*~i~'s were determined using an endoproteinase-coupled microfluidic capillary electrophoresis (MCE) assay \[[@R99]\]. UNC0321 (Morrison *K*~i~ = 63 pM) was about 40-fold more potent than UNC0224 (Morrison *K*~i~= 2.6 nM) and 250-fold more potent than BIX01294 (Morrison *K*~i~= 16 nM) \[[@R97]\]. While UNC0224 was equipotent against G9a and GLP, UNC0321 showed some selectivity for G9a (IC~50~ = 6 nM, AlphaScreen) over GLP (IC~50~ = 23 nM, AlphaScreen). In addition, UNC0321 was inactive (IC~50~ \> 40 µM, ThioGlo) against other PKMTs, SET7/9 and SETD8, as well as PRMT3 \[[@R97]\]. While highly potent in biochemical assays, UNC0321 was less potent in cellular assays compared to BIX01294.

To improve cellular potency of this series, new analogs aimed at increasing lipophilicity, thus cell membrane permeability, while maintaining high *in vitro* potency were designed and synthesized. Among the newly synthesized compounds, UNC0638 (Fig. **[4](#F4){ref-type="fig"}**) had excellent *in vitro* potency (Morrison *K*~i~ G9a = 3.7 nM; *K*~i~ = 3.0 nM) and was \> 100-fold selective over a wide range of epigenetic and non-epigenetic targets \[[@R100]\]. Michaelis-Menten kinetics found UNC0638 was indeed competitive with the peptide substrate instead of the SAM cofactor. This mechanism of action was confirmed by X-ray crystal structure of the G9a-UNC0638-SAH complex (2.56 Å resolution, PDB: 3RJW) which showed UNC0638 occupying the substrate binding groove and lysine binding channel, not the SAM binding pocket -- the same binding mode that was previously observed for UNC0224 (see Fig. **[3B](#F3){ref-type="fig"}**). More importantly, UNC0638, which possesses balanced *in vitro* potency and physicochemical properties aiding cell penetration, had excellent potency in cellular assays and low cell toxicity. UNC0638 treatment of a variety of cell lines resulted in reduction of global H3K9me2 levels equivalent to that observed for shRNA knockdown of G9a/GLP. It significantly reduced the H3K9me2 mark at the promoter of known G9a-regulated endogenous genes and did not reduce the H3K9me2 mark at the promoter of a non-G9a-regulated gene. In addition, UNC0638 significantly reduced the clonogenicity of MCF7 cells and disproportionately affected a number of genomic loci encoding microRNAs. In mouse embryonic stem (mES) cells, UNC0638 reactivated a retroviral reporter gene and G9a-silenced endogenous genes in a concentration dependent manner without promoting differentiation. Furthermore, UNC0638 significantly reduced H3K9me2 levels at the promoter of the retroviral long terminal repeat and G9a-regulated genes and indirectly induced DNA hypomethylation in mES cells \[[@R100]\]. The combination of high potency, excellent selectivity, and robust on-target activities in cells makes UNC0638 a valuable tool for further investigating the biological function of G9a and GLP and their role in health and disease \[[@R101]\].

Chang and co-workers also designed and synthesized quinazoline analogs based on the previously reported GLP-BIX01294 X-ray co-crystal structure and discovered compound E72 (Fig. **[4](#F4){ref-type="fig"}**) as a potent G9a and GLP inhibitor (IC~50~ GLP = 100 nM) with binding affinities determined by ITC (*K*~d~ GLP = 136 nM; G9a = 164 nM) \[[@R102]\]. A brief selectivity study showed E72 was inactive against H3K9 PKMT Suv39H2 with no inhibition at 5 µ M \[[@R102]\]. The X-ray co-crystal structure of the GLP-E72 complex in the presence of SAH (2.19 Å, PDB: 3MO5) showed that E72 occupied both the surface of the peptide binding groove and the lysine binding channel, in an analogous manner to UNC0224 with G9a (see Fig. **[4](#F4){ref-type="fig"}** inset for an overlay of E72 with BIX01294 and UNC0224) \[[@R102]\]. In three separate cell types, E72 was significantly less toxic than BIX01294 at compound concentrations of 10 µ M and was able to reactivate K-ras-mediated epigenetic silencing of the Fas gene in NIH 3T3 cells \[[@R102]\].

3.. PROTEIN ARGININE METHYLTRANSFERASES (PRMTs)
===============================================

Arginine residues of various histone and protein substrates can be mono- or dimethylated, and depending on the type of arginine methyltransferase, dimethlyation can occur in either a symmetric (one methyl group on each of the two terminal N atoms) or asymmetric (both methyl groups on the same terminal N atom) manner (Scheme **[1B](#S1){ref-type="scheme"}**). These enzymes transfer a methyl group from SAM to a terminal (or ω) guanidino nitrogen of arginine, resulting in SAH and methylarginine. To date, about nine human PRMTs have been characterized and are mainly classified as type I or type II enzymes \[[@R59]\]. Both types catalyze the formation of the monomethylarginine (MMA) intermediate. Type I enzymes (PRMT1--4, 6, and 8) then lead to the formation of asymmetric dimethylarginines (aDMA); whereas, type II enzymes (PRMT5, 7, and 9/FBXO11) form symmetrical dimethylarginine side chains (sDMA) \[[@R59], [@R103], [@R104]\]. In addition, PRMT7 exhibits type III enzymatic activity, the ability to selectively monomethylate certain substrates \[[@R59],[@R105]\]. Type IV activity has also been described, where the internal guanidino nitrogen atom is monomethylated, but this has only been documented in yeast \[[@R106]\]. Type I methyltransferase activity was recently demonstrated for PRMT2, albeit very weak \[[@R59], [@R107]\]. Also, while type II PRMT activity has been proposed for FLAG-PRMT9/hFBXO11 \[[@R108]\], none was detected with GST-purified hFBXO11 and GST-purified or HA-tagged DRE-1, the *C. elegans* ortholog \[[@R109]\]. Catalytic activity for PRMT9/4q31 has yet to be demonstrated \[[@R59]\]. PRMTs usually methylate glycine- and arginine-rich patches (so-called GAR motifs) \[[@R106], [@R110]\] except for PRMT4 (CARM1) which instead has an affinity toward proline, glycine, methionine, and arginine-rich sequences (PGM motifs) \[[@R111], [@R112]\]. PRMT5 has also shown an affinity for PGM motifs, in select cases \[[@R111]\].

PRMTs play a key role in transcriptional regulation, protein and RNA subcellular localization, RNA splicing, DNA damage repair and signal transduction \[[@R113]\]. Arginine methylation has been implicated in the positive and negative regulation of transcription. At least two methyltransferases, PRMT1 and PRMT4 (CARM1), have been linked to transcriptional activation. PRMT1 serves as a diverse regulator of protein function, responsible for the bulk (ca. 85%) of total arginine methyltransferase activity, and has the ability to methylate H4R3. PRMT4 (CARM1) was identified as a steroid receptor coactivator and can catalyze the methylation of H3R2, H2R17, and H3R26. Certain transcription factors (NR, p53, YY1, NF-κB) recruit these enzymes to specific promoters where they activate transcription. In contrast, PRMT5 methylates H3R8 and H4R3 and serves as a strong repressor of numerous genes. For example, PRMT5 negatively regulates the expression of tumor suppressor genes ST7 and NM23 \[[@R63]\].

3.1.. PRMT Inhibitors
---------------------

In 2004, Bedford and co-workers discovered the first non-nucleoside specific inhibitors of PRMTs using a random screening approach \[[@R114]\]. A diverse library of 9,000 compounds from ChemBridge was screened and nine of these compounds were identified as low micromolar inhibitors (0.15--6.9 µM) of *in vitro* methylation of the RNA binding protein, Npl3p, by the yeast Hmt1p arginine methyltransferase. These hits, named arginine methyltransferase inhibitors (AMIs), also inhibited human PRMT1, a mammalian orthologue of Hmt1p, with potency ranging from 0.19 to 16.3 µM (Fig. **[5](#F5){ref-type="fig"}**) \[[@R114]\].

To determine specificities, the AMIs were screened against a panel of other type I PRMTs (PRMT3, 4, and 6). Although each of the nine AMIs initially inhibited all of the PRMTs tested, displaying no specificity for individual type I PRMTs \[[@R114]\], a subsequent report found AMI-1 was selective over type II PRMT5 \[[@R115]\]. Furthermore, AMI-1 and -6 were selective *in vitro* against several lysine methyltransferases including Suv39H1, Suv39H2, SET7/9, and DOT1. Cellular activity studies in HeLa cells showed AMI-1, but not -6, was able to inhibit hPRMT1, decreasing methylation levels of the GFP-Npl3 fusion \[[@R114]\]. AMI-1 was also screened against sirtuin, a class III histone deacetylase (HDAC), due to the minor similarity of the binaphthylurea motif of AMI-1 to the known sirtuin inhibitor, suramin. AMI-1 inhibited sirtuin, albeit with decreased potency relative to suramin (IC~50~ on SIRT1: AMI-1, 32 µ M; suramin, 300 nM) \[[@R116]\].

Several groups have since used the AMIs as leads for PRMT drug discovery. Using the dye-like core of AMI-5 and -6 as a lead scaffold, a number of analogs were synthesized \[[@R117]\]. The most potent of these analogs was compound **1** (IC~50~ hPRMT1 = 4.8 µ M), which was less potent than AMI-5 (Fig. **[6](#F6){ref-type="fig"}**). Cellular activity data was not reported \[[@R117]\]. The AMI-5 (eosin) scaffold was subsequently simplified to curcumin-like structures \[[@R118]\] containing bromo- and dibromophenol moieties \[[@R119]\]. These analogs were screened against a panel of methyltransferases. Several compounds, including **2** and **3** (Fig. **[6](#F6){ref-type="fig"}**), were selective for PRMT4 (CARM1) over PRMT1 and SET7/9 at concentrations of 100 µ M \[[@R119]\].

In addition, Bonham and co-workers reported their efforts to generate a less polar version of AMI-1 while still maintaining PRMT potency \[[@R115]\]. Using the aminonaphthol sulfonate scaffold of AMI-1 as the core, analogs were synthesized by adding structural attributes of AMI-6 and -9. The most potent hybrid, compound **4** (IC~50~ hPRMT1 = 4.2 µM; hPRMT4 = 2.6 µ M), contained both the dichlorotriazine group of AMI-6 and the azo moiety of AMI-9 (Fig. **[6](#F6){ref-type="fig"}**). Selectivity studies showed compound **4** inhibited both type I and type II PRMTs but was mostly inactive against lysine methyltransferase SET7/9. Since PRMTs have been shown to regulate T-helper cell activation and cytokine secretion \[[@R120]-[@R122]\], the effect of compound **4** on cytokine expression was also examined. Indeed, compound **4** enhanced T-helper cell proliferation without affecting cell viability and decreased IFN-γ and IL-4 production of type I and type II T-helper cells, respectively, thereby interfering with IL-4 promoter activity and impairing the interaction between PRMT1 and NIP45 \[[@R115]\].

A high throughput screening effort by Purandare and coworkers led to the identification of pyrazole amide 5 as an initial hit (Fig. **[7](#F7){ref-type="fig"}**), which after preliminary optimization gave compound 6 (IC~50~ hPRMT4 = 80 nM) as a potent and selective inhibitor of PRMT4 (CARM1) \[[@R123]\], albeit poor permeability \[parallel artificial membrane permeability assay (PAMPA)\] and pharmacokinetic (PK) properties \[[@R124], [@R125]\]. Further hit to lead optimization of this class by separate groups led to two potent derivatives: **7** and **8** (Fig. **[7](#F7){ref-type="fig"}**) with IC~50~'s \< 100 nM, although the compounds were either not active in cellular assays or the data were not reported \[[@R124], [@R126]\]. However, replacing the amide functionality with the 1,3,4-oxadiazole moiety in **7** improved membrane permeability (PAMPA) \[[@R124]\]. Compounds **6** and **7** were found to be significantly less potent against other type I PRMTs (PRMT1 and 3, IC~50~ \> 25 µM) \[[@R123], [@R124]\] and **8** was selective against both PRMT1 and lysine methyltransferase SET7/9 (IC~50~ \> 100 µ M) \[[@R126]\]. A subsequent report identified compound **9** as a potent pyrazole derivative (IC~50~ mPRMT4 = 0.20 µ M, Fig. **[7](#F7){ref-type="fig"}**) with an improved PK profile in rats, although it did not show cellular activity when tested in the MTT cell viability assay \[[@R125]\]. Concurrently, an additional screening effort by Wan and co-workers identified benzo\[*d*\]imidazole related analogs as hits against PRMT4 (CARM1) with low micromolar potency \[[@R127]\]. Hit to lead optimization and SAR exploration led to the most potent analog in this series, compound **10** (IC~50~ hPRMT4 = 70 nM, Fig. **[7](#F7){ref-type="fig"}** inset), which was significantly less active against other type I PRMTs (PRMT1 and 3, IC~50~ \> 25 µ M) \[[@R127]\].

The first target based virtual screening study for PRMTs was reported by Spannhoff and co-workers in 2007 \[[@R128]-[@R130]\]. In this study, a combination of molecular docking and pharamacophore-based filtering was used to virtually screen hPRMT1 and fungal RmtA, a PRMT1 homologue, against the NCI diversity subset consisting of 1990 compounds. Homology models of both enzymes were constructed from the known rat PRMT3 X-ray crystal structure (PDB: 1F3L). In order to target the histone binding pocket, SAH was included as part of the protein during docking. Compounds that were successfully docked were then tested *in vitro* against RmtA and recombinant hPRMT1. In this study, seven of the 36 virtual hits were able to inhibit RmtA and hPRMT1 with micromolar potency (IC~50~ hPRMT1 = 2--90 µ M) \[[@R128]\]. Hit validation was conducted in cancer cells using antibody-mediated detection of histone hypomethylation caused by inhibition of PRMT1. Two of the hits, allantodapsone and stilbamidine (Fig. **[8](#F8){ref-type="fig"}**), inhibited methylation at PRMT1 target H4R3 in a dose-dependent manner while having only a marginal effect on methylation levels of PKMT target H3K4. In a reporter gene functional assay with MCF7a cells, both inhibitors showed a dose-dependent reduction of estrogen receptor activation by estradiol. In addition, kinetic assays showed allantodapsone and stilbamidine did not inhibit RmtA in a SAM-competitive manner but were rather competitive with regard to the histone substrate, as expected \[[@R128]\].

Based on the success of the structure-based virtual screen to discover potent and cell-penetrant PRMT inhibitors, a larger virtual screening effort was conducted using the ChemBridge compound collection containing 328,000 compounds \[[@R129]-[@R131]\]. The database was first filtered using a simple pharmacophore search resulting in an abbreviated library of ca. 6200 compounds. These compounds were then docked into the substrate binding pocket of PRMT1, resulting in nine inhibitors of hPRMT1 with IC~50~ values ranging from 13 to 37 μM \[[@R131]\]. The three most potent compounds, **11**--**13**, are represented in Fig. (**[8](#F8){ref-type="fig"}**).

As an alternative approach for identifying new PRMT inhibitors, Spannhoff and co-workers performed a fragment-based virtual screen of ca. 900 fragment-like leads with molecular weights below 200 g/mol and identified an α-methylthioglycolic amide compound as a micromolar inhibitor of RmtA \[[@R129],[@R130],[@R132]\]. A subsequent structure similarity search led to the discovery of RM65 (Fig. **8**) as an equipotent inhibitor of RmtA and hPRMT1 *in vitro* (IC~50~ hPRMT1 = 55 µ M). A cursory selectivity study found RM65 was not active against PKMT SET7/9 at a concentration of 50 µ M. In cancer cells, histone hypomethylation was observed at PRMT1 target H4R3. Additionally, while the virtual screen was conducted with fragments binding to the substrate binding pocket, docking studies have suggested a bisubstrate binding mode for RM65, targeting both the substrate and cofactor binding sites \[[@R132]\].

An alternative mechanism of inhibiting PRMT-mediated arginine methylation was recently reported. Rather than developing inhibitors of the enzyme active site, Feng and co-workers developed small molecules that target the substrate, blocking PTMs on H4 by H4-modifying enzymes \[[@R133]\]. The naphthalene-sulfonate (NS) analogs were discovered through a similarity structure search of a weak hit identified from a virtual screen of the ChemBridge compound collection. The most potent derivative, NS-1 (Fig. **[9](#F9){ref-type="fig"}**), was initially characterized as a substrate-competitive PRMT1 inhibitor with micromolar potency (IC~50~ hPRMT1 = 13 µ M) \[[@R133]\]. However, after a variety of kinetic and biophysical studies, NS-1 and similar structural analogs including AMI-1 were found to interact directly with the substrate, not the enzyme, blocking PRMT1-mediated arginine methylation. In a selectivity study, NS-1 was found to be significantly less potent against PRMT4 (CARM1) (IC~50~ mPRMT4 \~ 2 mM) \[[@R133]\]. Unlike PRMT1, PRMT4 (CARM1) targets H3 and does not methylate GAR sequences. In addition, Selvi and co-workers isolated the small molecule TBBD (ellagic acid) from pomegranate extract and found it inhibited the methyltransferase activity of PRMT4 (CARM1) in a substrate-targeting manner, selectively blocking methylation of H3R17 (Fig. **[9](#F9){ref-type="fig"}**) \[[@R134]\]. These and other substrate sequence-specific inhibitors may emerge as useful tools for mechanistic study of arginine methylation and other epigenetic modifications.

4.. FUTURE DIRECTIONS IN DRUG DISCOVERY
=======================================

The interest in epigenetic misregulation from the scientific community over the past decade is bound to increase in the future as more scientists realize its profound effect on genome function \[[@R135]\]. Understanding the mechanisms behind cell differentiation and gaining the ability to control them by inhibiting chromatin modifying enzymes holds much promise for combating human disease. For example, it is now understood that epigenetic changes work in concert with genetic changes to promote oncogenesis. Recently, viability of this approach has been confirmed by promising cancer therapy clinical data \[[@R136]\]. These discoveries drive the interest in solving the mystery behind cell differentiation and deciphering the histone code.

As new inhibitors for various methyltransferases emerge, mechanisms by which PTM marks are made and their impact on nucleosome structure and remodeling are becoming better understood. Thus far, the histone code has proven to be a significantly more complex entity than for example, the genetic code, where a direct mapping between codons and amino acids exists \[[@R137]\]. Certain correlations between specific PTMs of the histones and individual processes have been identified, *inter alia,* methylation of H3K4, H3K36 and H3K79 has been linked to activation of transcription, H3K79 and H4K20 to DNA repair, and H3K9 and H3K27 have been correlated to transcription repression \[[@R138]\]. Interestingly, these correlations are not always conserved amongst species and organisms \[[@R139]\].

The discovery effort is quickly gaining momentum and several potent, selective inhibitors of methyltransferases have already been identified *vide supra*. Future efforts should focus on continued discovery of potent, selective, and cell penetrant inhibitors. A number of traditional techniques have been employed in the discovery of the existing inhibitors. High throughput screening (HTS) and virtual screening (VS) are responsible for identifying most of these inhibitors. As the number of available HTS compatible biological assays increases, these approaches are likely to continue to generate structurally diverse hits as good starting points for medicinal chemistry optimization.

Increased availability of high resolution 3-dimensional (3D) structures of methyltransferases in *apo*- and *holo*- states provides medicinal and computational chemists a unique opportunity to design and synthesize novel inhibitors. Reviewing the existing crystal structure data, two distinct cofactor conformations can be noted for PKMTs and PRMTs. Fig. (**[10](#F10){ref-type="fig"}**) shows the superimposition of the cofactor conformations extracted from the currently available crystal structures. Amongst the PKMTs, with the exception of DOT1L, the cofactor (SAM or SAH) adopts a highly conserved conformation, sometimes referred to as the "U shape" (Fig. **[10A](#F10){ref-type="fig"}**). On the other hand, a different and a more extended cofactor conformation is observed in four of the PRMTs, as well as for DOT1L (Fig. **[10B](#F10){ref-type="fig"}**). This consistent cofactor conformation may provide a molecular basis for ligand-based rational design as well as for pharmacophore-based screening. Although inhibitor selectivity could be a potential issue for this target class approach \[[@R140], [@R141]\], one may reasonably expect that a high degree of selectivity can be achieved by targeting diversified residues in the binding pockets based on what we have learned from the discovery of highly selective kinase inhibitors. Drawing upon the analogy between SAM/methyltransferase and the ATP/kinase relationships, many of the techniques previously applied to studying kinases could very well be carried over to the investigation of methyltransferases \[[@R135]\]. To date, few cofactor-competitive inhibitors have been reported. Thus, progress on a systematic approach to discovering SAM-competitive inhibitors is keenly awaited.

In addition, a fragment based drug discovery approach \[[@R142], [@R143]\], where weakly binding fragments are identified and then grown or combined to produce higher affinity molecules, might be employed in discovering novel methyltransferase inhibitors. Taking note of the close proximity observed between the cofactor and substrate binding pockets, one might envision designing a ligand that occupies both binding sites. Finally, molecules that interact with an allosteric site may yield quality methyltransferase inhibitors.

The scientific community eagerly awaits the discovery of more, high quality, well characterized chemical probes \[[@R75]\] of PKMTs and PRMTs. A 'tool-kit' of such chemical probes would permit biological hypotheses to be tested in cell-based and animal models of human biology and disease with high confidence, thus providing the biomedical community with excellent tools for further investigating the biology of methyltransferases and their role in chromatin remodeling and other PTMs.
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![SAM-dependent methylation of lysine (**A**) and arginine (**B**) residues.](TOCHGENJ-5-72_S1){#S1}

![GLP-H3 co-crystal structure (PDB: 2RFI, H3K9me2 is shown in green) with SAH (cyan) illustrating the hydrophobic channel connecting the cofactor binding site and the substrate binding pocket.](TOCHGENJ-5-72_F1){#F1}

![Lysine methyltransferase inhibitors (IC~50~ values in parentheses with corresponding enzyme).](TOCHGENJ-5-72_F2){#F2}

![**A**) GLP-BIX01294 complex (PDB: 3FPD, BIX01294 is shown in orange) with SAH (cyan) superimposed with GLP-H3 co-crystal structure (PDB: 2RFI, H3 backbone (ribbon) and H3K9me2 are shown in green). **B**) G9a-UNC0224 complex (PDB: 3K5K, UNC0224 is shown in grey) with SAH (cyan) superimposed with GLP-H3 co-crystal structure (H3K9me2 is shown in green).](TOCHGENJ-5-72_F3){#F3}

![Lysine methyltransferase inhibitors (Morrison *K*~i~ or *K*~d~ values in parentheses with corresponding enzyme); inset, E72 (green) super-imposed with BIX01294 (orange) and UNC0224 (grey).](TOCHGENJ-5-72_F4){#F4}

![Select examples of the first non-nucleoside arginine methyltransferase inhibitors (AMIs) identified from random screening (IC~50~ values in parentheses with corresponding enzyme).](TOCHGENJ-5-72_F5){#F5}

![Synthetic analogs of the original AMI series identified as PRMT inhibitors (IC~50~ values in parentheses with corresponding enzyme).](TOCHGENJ-5-72_F6){#F6}

![PRMT inhibitors designed from the high throughput screening hit, pyrazole amide **5**; inset, Benzo\[*d*\]imidazole related analog identified as a PRMT inhibitor (IC~50~ values in parentheses with corresponding enzyme).](TOCHGENJ-5-72_F7){#F7}

![PRMT inhibitors identified from virtual screens (IC~50~ values in parentheses with corresponding enzyme).](TOCHGENJ-5-72_F8){#F8}

![Substrate-targeting PRMT inhibitors (IC~50~ values in parentheses with corresponding enzyme and substrate).](TOCHGENJ-5-72_F9){#F9}

![Superimposition of various cofactor (SAM or SAH) conformations extracted from currently available crystal structures. **A**) Structures of cofactors bound to nine human PKMTs, including G9a (PDB: 3K5K), GLP (PDB: 3MO0), SETMAR (PDB: 3BO5), SUV39H2 (PDB: 2R3A), SETD2 (PDB: 3H6L), SMYD3 (PDB: 3MEK), MLL (PDB: 2W5Z), SET7/9 (PDB: 1O9S) and SETD8 (PDB: 1ZKK). **B**) Structures of cofactors bound to human DOT1L (PDB: 1NW3) and three human PRMTs, including PRMT4 (CARM1) (PDB: 2V74), PRMT1 (PDB: 1ORI) and PRMT3 (PDB: 2FYT).](TOCHGENJ-5-72_F10){#F10}

###### 

Protein Methyltransferases, their Methylation Marks, and Links to Disease

  Methyltransferase   Major Target Site(s)                               Function or Links to Disease
  ------------------- -------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  SUV39H1             H3K9                                               Increased expression in colorectal tumors \[[@R20]\]
  SUV39H2             H3K9                                               Mice lacking both SUV39H genes showed cytogenetic abnormalities and increased incidence of lymphoma \[[@R21]\]
  SUV420H1            H4K20                                              Function or link to disease not yet elucidated
  SUV420H2            H4K20                                              Decreased expression found in human breast cancer cells \[[@R22]\]
  EZH1                H3K27                                              Function or link to disease not yet elucidated
  EZH2                H3K27                                              Overexpressed in various human cancers, including prostate, breast, colon, skin, and lung cancers; \[[@R23]\] dominant, gain-of-function mutation (Tyr641) increases H3K27me3 levels leading to tumorigenesis; \[[@R24]\]malignant phenotype of follicular and diffuse-large B-cell lymphomas of the germinal-center origin is the result of the overall gain of function \[[@R25]\]
  G9a                 H3K9, p53K373                                      Overexpressed in various human cancers including leukemia, prostate carcinoma, hepatocellular carcinoma and lung cancer \[[@R26]-[@R29]\]
  GLP                 H3K9, p53K373                                      Overexpressed in gland tumors \[[@R30]\]
  SETDB1              H3K9                                               Cooperation with DNA methyltransferase silencing of promoter regions in tumor cells \[[@R31]\]
  SET7/9              H3K4, p53K372, p65 subunit NF-κB                   Modulates p53 activity in human cancer cells; \[[@R32]\] regulates NF-κB-dependent inflammatory genes \[[@R33]\]
  SETD8               H4K20, p53K372, p53K382                            Implicated in cell cycle dependent gene silencing and mitotic regulation; \[[@R34],[@R35]\] suppresses p53 dependent transcription \[[@R36]\]
  MLL1                H3K4                                               Mutations/rearrangements observed in patients with acute leukemia including MLL partial tandem duplications and MLL fusions \[[@R37]-[@R39]\]
  MLL2                H3K4                                               Mutations of MLL2 found in renal cell carcinoma \[[@R40]\]and Kabuki syndrome \[[@R41]\]
  MLL3                H3K4                                               Function or link to disease not yet elucidated \[[@R42]\]
  MLL4                H3K4                                               Serves as a cellular target for hepatitis B virus in liver oncogenesis \[[@R43]\]
  SMYD2               H3K36, p53K370                                     Suppresses p53 transcriptional activity \[[@R44]\]
  SMYD3               H3K4                                               Overexpression correlated with the development of colorectal and hepatocellular carcinoma; \[[@R45]\] enhanced breast cancer cell growth due to overexpression \[[@R46]\]
  NSD1                H3K36, H4K20                                       NSD1 deletions and intragenic mutations are identified in patients with Sotos and Weaver syndromes \[[@R47]\]
  NSD2                H3K4, H3K27, H3K36, H4K20                          Translocated in some cases of myeloma \[[@R48]\]
  NSD3                H3K4, H3K27, H3K36                                 Fused with NUP98 in acute myeloid leukemia; \[[@R49]\] amplified in breast cancers \[[@R50]\]
  DOT1L               H3K79                                              Recruited by MLL fusion partners to Hox genes; directly involved in acute myeloid leukemia \[[@R51],[@R52]\]
  PRMT1               H4R3, NAB2p, NPL3p, ERαR260 and other GAR motifs   Coactivator of hormone receptor function; aberrant expression observed in several tumor states including breast and colon cancers; \[[@R53]-[@R56]\]deregulation of H4R3 suggestive marker of prostate cancer; \[[@R57]\]essential component of MLL oncogenic transcriptional complex and activity required for malignant transformation \[[@R58]\]
  PRMT2               H4(site of methylation unknown)\[[@R59]\]          Coactivator of both the androgen receptor and ERα \[[@R59]\]
  PRMT4 (CARM1)       H3R2, H3R17, H3R26, and other PGM motifs           Steroid receptor coactivator; overexpressed in both human breast tumors and castration-resistant prostate cancer; \[[@R60]-[@R62]\]knockdown impedes androgen receptor signaling
  PRMT5               H3R8, H4R3, H2AR3                                  Acts as a strong repressor of numerous genes; recruited to the promoters of tumor suppressor genes such as ST7 and NM23; \[[@R63]\]overexpression observed in a variety of lymphoma and leukemia cells, \[[@R64],[@R65]\]gastric carcinoma,\[[@R66]\]and immortalized fibroblast cells \[[@R63]\]
  PRMT6               H3R2, H4R3, H2AR3                                  Transcriptional repressor \[[@R59]\]
  PRMT7               H4R3, H2AR3                                        Downregulation sensitizes cancer cells to camptothecin treatment \[[@R67]\]

[^1]: These authors contributed equally to this review.
